Bank of New York Mellon’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $491K | Buy |
+105,742
| New | +$274K | ﹤0.01% | 3761 |
|
|
2025
Q2 | – | Sell |
-50,826
| Closed | -$62K | – | 4180 |
|
|
2025
Q1 | $62K | Hold |
50,826
| – | – | ﹤0.01% | 4040 |
|
|
2024
Q4 | $65.6K | Buy |
50,826
+8,105
| +19% | +$19.4K | ﹤0.01% | 4063 |
|
|
2024
Q3 | $117K | Sell |
42,721
-21,702
| -34% | -$53.3K | ﹤0.01% | 3993 |
|
|
2024
Q2 | $146K | Buy |
+64,423
| New | +$196K | ﹤0.01% | 3991 |
|
|
2024
Q1 | – | Sell |
-23,080
| Closed | -$38.3K | – | 4217 |
|
|
2023
Q4 | $38.3K | Hold |
23,080
| – | – | ﹤0.01% | 4180 |
|
|
2023
Q3 | $44.3K | Hold |
23,080
| – | – | ﹤0.01% | 4175 |
|
|
2023
Q2 | $33.2K | Buy |
23,080
+1
| +0% | +$2 | ﹤0.01% | 4229 |
|
|
2023
Q1 | $48.5K | Hold |
23,079
| – | – | ﹤0.01% | 4203 |
|
|
2022
Q4 | $26.1K | Hold |
23,079
| – | – | ﹤0.01% | 4322 |
|
|
2022
Q3 | $38K | Hold |
23,079
| – | – | ﹤0.01% | 4361 |
|
|
2022
Q2 | $30K | Hold |
23,079
| – | – | ﹤0.01% | 4446 |
|
|
2022
Q1 | $37K | Hold |
23,079
| – | – | ﹤0.01% | 4562 |
|
|
2021
Q4 | $48K | Hold |
23,079
| – | – | ﹤0.01% | 4508 |
|
|
2021
Q3 | $90K | Sell |
23,079
-1
| -0% | -$3 | ﹤0.01% | 4349 |
|
|
2021
Q2 | $74K | Sell |
23,080
-76,821
| -77% | -$273K | ﹤0.01% | 4264 |
|
|
2021
Q1 | $216K | Sell |
99,901
-7,509
| -7% | -$16.8K | ﹤0.01% | 4026 |
|
|
2020
Q4 | $241K | Sell |
107,410
-3,361
| -3% | -$8.82K | ﹤0.01% | 3915 |
|
|
2020
Q3 | $296K | Sell |
110,771
-1,861
| -2% | -$5.21K | ﹤0.01% | 3724 |
|
|
2020
Q2 | $344K | Sell |
112,632
-1,758
| -2% | -$4.42K | ﹤0.01% | 3652 |
|
|
2020
Q1 | $224K | Buy |
114,390
+1
| +0% | +$2 | ﹤0.01% | 3705 |
|
|
2019
Q4 | $327K | Buy |
114,389
+1,648
| +1% | +$5.73K | ﹤0.01% | 3767 |
|
|
2019
Q3 | $414K | Buy |
112,741
+17,426
| +18% | +$63K | ﹤0.01% | 3644 |
|
|
2019
Q2 | $395K | Buy |
95,315
+75,963
| +393% | +$329K | ﹤0.01% | 3712 |
|
|
2019
Q1 | $99K | Sell |
19,352
-578
| -3% | -$2.77K | ﹤0.01% | 4006 |
|
|
2018
Q4 | $68K | Hold |
19,930
| – | – | ﹤0.01% | 4019 |
|
|
2018
Q3 | $120K | Sell |
19,930
-1
| -0% | -$6 | ﹤0.01% | 4011 |
|
|
2018
Q2 | $127K | Sell |
19,931
-5,878
| -23% | -$28.6K | ﹤0.01% | 3976 |
|
|
2018
Q1 | $122K | Buy |
25,809
+5,879
| +29% | +$27.4K | ﹤0.01% | 4020 |
|
|
2017
Q4 | $67K | Sell |
19,930
-2,191
| -10% | -$5.54K | ﹤0.01% | 4158 |
|
|
2017
Q3 | $48K | Buy |
22,121
+1,323
| +6% | +$2.62K | ﹤0.01% | 4108 |
|
|
2017
Q2 | $51K | Buy |
20,798
+121
| +0.6% | +$322 | ﹤0.01% | 4128 |
|
|
2017
Q1 | $48K | Sell |
20,677
-1,273
| -6% | -$1.92K | ﹤0.01% | 4144 |
|
|
2016
Q4 | $22K | Buy |
21,950
+779
| +4% | +$692 | ﹤0.01% | 4209 |
|
|
2016
Q3 | $24K | Sell |
21,171
-3,640
| -15% | -$6.47K | ﹤0.01% | 4207 |
|
|
2016
Q2 | $36K | Buy |
24,811
+84
| +0.3% | +$123 | ﹤0.01% | 4230 |
|
|
2016
Q1 | $35K | Hold |
24,727
| – | – | ﹤0.01% | 4125 |
|
|
2015
Q4 | $41K | Hold |
24,727
| – | – | ﹤0.01% | 4213 |
|
|
2015
Q3 | $58K | Sell |
24,727
-80
| -0.3% | -$189 | ﹤0.01% | 4224 |
|
|
2015
Q2 | $68K | Sell |
24,807
-51,279
| -67% | -$155K | ﹤0.01% | 4121 |
|
|
2015
Q1 | $255K | Sell |
76,086
-5,106
| -6% | -$18.2K | ﹤0.01% | 3831 |
|
|
2014
Q4 | $282K | Sell |
81,192
-2,520
| -3% | -$11.1K | ﹤0.01% | 3795 |
|
|
2014
Q3 | $421K | Buy |
83,712
+6,442
| +8% | +$50.2K | ﹤0.01% | 3689 |
|
|
2014
Q2 | $1.07M | Buy |
77,270
+56,153
| +266% | +$699K | ﹤0.01% | 3275 |
|
|
2014
Q1 | $323K | Hold |
21,117
| – | – | ﹤0.01% | 3714 |
|
|
2013
Q4 | $171K | Buy |
+21,117
| New | +$195K | ﹤0.01% | 3898 |
|
Other funds holding GALT
WANY
GWM
RGF
SA
Bank of New York Mellon's GALT Position: Q2 2026 in Review
Bank of New York Mellon opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 105,742 shares worth $491K. The stake represents ﹤0.01% of the portfolio and ranks #3761 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in GALT as recently as Q1 2025.
Bank of New York Mellon first reported a position in GALT in Q4 2013 and has held it in 46 quarters since. The position peaked at $1.07M in Q2 2014. 47 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Bank of New York Mellon held 105,742 shares of Galectin Therapeutics worth $491K as of Q2 2026.
- Galectin Therapeutics was a new Bank of New York Mellon position in Q2 2026.
- Galectin Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3761 holding.
- Bank of New York Mellon first reported a position in Galectin Therapeutics in Q4 2013 and has held it in 46 quarters since.
- Bank of New York Mellon's Galectin Therapeutics position peaked at $1.07M in Q2 2014.
- 47 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.